1  (1.03 to 1.75) to 2.04 (1.49 to 2.86)), and zolmitriptan (1.47 (1.04 to 2.08) to 1.96 (1.39 to 2.86)

2 t least 2 of the first 3 attacks switched to zolmitriptan, 2.5 mg, to treat the remaining 3 attacks;

3  hours in each attack escalated treatment to zolmitriptan, 2.5 mg.

4 rade III and IV treated up to 6 attacks with zolmitriptan, 2.5 mg; (2) step care across attacks (n =

5  telcagepant 150 mg (n=333) or 300 mg (354), zolmitriptan (345), or placebo (348).

6           Efficacy of telcagepant 300 mg and zolmitriptan 5 mg were much the same, and both were more

7 g, 37% taking telcagepant 300 mg, 51% taking zolmitriptan 5 mg, and 32% taking placebo.

8 migraine with efficacy comparable to that of zolmitriptan 5 mg, but with fewer associated adverse eff

9 th either oral telcagepant 150 mg or 300 mg, zolmitriptan 5 mg, or placebo.

10 ne (9/10 cells), sumatriptan (2/3 cells) and zolmitriptan (9/15 cells) but not by saline (3/10 cells)

11 ta for sumatriptan succinate nasal spray and zolmitriptan, eletriptan hydrobromide, almotriptan malat

12 l, eletriptan, rizatriptan, sumatriptan, and zolmitriptan had the best profiles and they were more ef

13 n and eletriptan, and a nasal formulation of zolmitriptan have been recently developed.

14                                              Zolmitriptan nasal spray has a rapid onset of action and

15 tain triptans (rizatriptan, sumatriptan, and zolmitriptan) were also associated with a higher risk of